Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Upadacitinib

FDA-approved product (tablet, extended release, oral), marketed as Rinvoq, Rinvoq Lq.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Upadacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Upadacitinib. Its therapeutic class is shown instead.

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Upadacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Upadacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

    NCT02925117 · start 2016-10-25

    Registered record
    Registry ID
    NCT02925117
    Conditions
    Atopic Dermatitis
    Interventions
    Upadacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10-25
    Completion
    2019-01-31
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Dermatitis
    InterventionUpadacitinib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

    NCT02706951 · start 2016-03-23

    Registered record
    Registry ID
    NCT02706951
    Conditions
    Rheumatoid Arthritis
    Interventions
    Methotrexate; Upadacitinib; Placebo Upadacitinib; Placebo Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03-23
    Completion
    2022-08-10
    Enrolment
    648

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionMethotrexate; Upadacitinib; Placebo Upadacitinib; Placebo Methotrexate
    PhasePhase 3
    Registry statusCompleted

  • A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

    NCT02720523 · start 2016-03-22

    Registered record
    Registry ID
    NCT02720523
    Conditions
    Rheumatoid Arthritis
    Interventions
    Placebo; Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-03-22
    Completion
    2022-06-07
    Enrolment
    197

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionPlacebo; Upadacitinib
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

    NCT02066389 · start 2014-03-26

    Registered record
    Registry ID
    NCT02066389
    Conditions
    Rheumatoid Arthritis
    Interventions
    Placebo; Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-26
    Completion
    2015-07-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionPlacebo; Upadacitinib
    PhasePhase 2
    Registry statusCompleted

  • PsoBest - The German Psoriasis Registry

    NCT01848028 · start 2008-01

    Registered record
    Registry ID
    NCT01848028
    Conditions
    Psoriasis; Psoriatic-arthritis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-01
    Completion
    2032-12
    Enrolment
    3,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Psoriatic-arthritis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting